Suche klinische Studie
Weitere Suchoptionen
202 Ergebnis(se)
Rekrutierende Studie = 
; Fortlaufende Studie = 
; Förderung durch ein IRDiRC-Mitglied = 
; ERN-Mitglied = 
Nationale klinische Studie(n)
VEREINIGTES KONIGREICH
Cambridgeshire
CAMBRIDGE
APRIL: Safety of Abatacept in Rheumatoid Arthritis Associated Interstitial Lung Disease (a feasibility trial)
Addenbrooke's Hospital
Addenbrookes Hospital
VEREINIGTES KONIGREICH
Greater London
LONDON
RBHIPF004 - A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease
National Heart and Lung Institute, Imperial College, Royal Brompton Campus
Interstitial Lung Disease Unit
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Sicherheit von Abatacept bei der Behandlung von interstitiellen Lungenerkrankungen (ILD) bei Patienten mit variablem Immundefekt (CVID) und ähnlichen Erkrankungen.
Institution: Information not provided - DE
DEUTSCHLAND
Nordrhein-Westfalen
KÖLN
BETTER-B: Eine internationale, multizentrische, randomisierte, kontrollierte Phase III-Studie zur Evaluation von Mirtazapin zur Linderung von Atemnot in Palliative Care
Universitätsklinikum Köln
Zentrum für Palliativmedizin
IRLAND
County Dublin
DUBLIN
BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care - IE
University College Dublin
UCD School of Medicine
ITALIEN
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care - IT
Institution: Information not provided - IT
DEUTSCHLAND
Baden-Württemberg
FREIBURG
ABASARC: Sicherheit und Wirksamkeit von Abatacept bei Patienten mit behandlungsresistenter Sarkoidose
Klinik für Pneumologie am Universitätsklinikum Freiburg
Klinik für Pneumologie
DEUTSCHLAND
Baden-Württemberg
HEIDELBERG
IMPALA-X: Eine offene, nicht kontrollierte, multizentrische klinische Studie mit inhaliertem Molgramostim bei Autoimmunpatienten mit Lungenalveolarproteinose
Thoraxklinik-Heidelberg gGmbH
Thoraxklinik Heidelberg
DEUTSCHLAND
Bayern
GAUTING
IMPALA-X: Eine offene, nicht kontrollierte, multizentrische klinische Studie mit inhaliertem Molgramostim bei Autoimmunpatienten mit Lungenalveolarproteinose
Asklepios-Fachkliniken München-Gauting
Klinik für Pneumologie
DEUTSCHLAND
Nordrhein-Westfalen
ESSEN
IMPALA-X: Eine offene, nicht kontrollierte, multizentrische klinische Studie mit inhaliertem Molgramostim bei Autoimmunpatienten mit Lungenalveolarproteinose
Universitätsklinikum Essen
DEUTSCHLAND
Nordrhein-Westfalen
ESSEN
IMPALA: Eine randomisierte, doppelblinde, Placebo-kontrollierte, multizentrische klinische Studie mit inhalativem Molgramostim bei Patienten mit autoimmuner Pulmonaler Alveolarproteinose
Universitätsmedizin Essen - Ruhrlandklinik
Klinik für Pneumologie
DEUTSCHLAND
Schleswig-Holstein
LÜBECK
IMPALA-X: Eine offene, nicht kontrollierte, multizentrische klinische Studie mit inhaliertem Molgramostim bei Autoimmunpatienten mit Lungenalveolarproteinose
Universitätsklinikum Schleswig-Holstein - Campus Lübeck
Medizinische Klinik III - Pneumologie
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
EXIST-2: A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) - ES (Phase III)
Institution: Information not provided - FR
FRANKREICH
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
ProCoCo: Procollagen-3 Driven Corticosteroids for Persistent Acute Respiratory Distress Syndrome
CHU de Marseille - Hôpital Nord
Service de réanimation médicale détresses respiratoires - Infections sévères
JAPAN
JAPAN
KUMAMOTO
ONE-BRIDGE: An Open-label, Standard Therapy as a Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of HLCM051(MultiStem) in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by Pneumonitis
Saiseikai Kumamoto Hospital
Respiratory Medicine & Surgery
JAPAN
JAPAN
KYOTO
ONE-BRIDGE: An Open-label, Standard Therapy as a Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of HLCM051(MultiStem) in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by Pneumonitis
University Hospital, Kyoto Prefectural University of Medicine
Department of Anesthesiology
KANADA
Ontario
TORONTO
A Phase 1 Study: The Determination of the Maximum Tolerable Dosage of Nebulized Sodium Nitroprusside in Adult Acute Lung Injury
Mount Sinai Hospital
NIEDERLANDE
Noord-Holland
AMSTERDAM
IMMEDIATE: Intravenous immunoglobulins as early treatment in newly diagnosed idiopathic inflammatory myopathies: a pilot study
Amsterdam UMC, locatie AMC
Afdeling Neurologie
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
Systems medicine analysis of sarcoidosis by targeting mTOR in a pilot study of sirolimus as treatment in patients with sarcoidosis (phase 2)
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
SEAL: Safety and Efficacy of Inhaled Pegylated Adrenomedullin (PEG-ADM) in Patients Suffering From Acute Respiratory Distress Syndrome (ARDS): a Double-blind, Randomized, Placebo-controlled, Multicenter Phase 2a/b Clinical Trial - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
The TRISTARDS Trial - ThRombolysIS Therapy for ARDS: A Phase IIb/III Operationally Seamless, Open-label, Randomised, Sequential, Parallel-group Adaptive Study to Evaluate the Efficacy and Safety of Daily Intravenous Alteplase Treatment Given up to 5 Days on Top of Standard of Care Compared With SOC Alone, in Patients With ARDS Triggered by COVID-19 - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
WIEN
Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS - a Randomised, Placebo-controlled, Double-blind Trial (Phase 2) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Allgemeine Anästhesie und Intensivmedizin
OSTERREICH
WIEN
WIEN
EXODUS: Extracorporeal Lung Assist Device in Acute Lung Impairment: A Randomized Controlled Study - AT
Allgemeines Krankenhaus der Stadt Wien
Intensivstation 13.i2
OSTERREICH
WIEN
WIEN
DeVENT: Decision Support System to Evaluate VENTilation in ARDS (acute respiratory distress syndrome) - AT
Allgemeines Krankenhaus der Stadt Wien
Intensivstation 13.i2
OSTERREICH
WIEN
WIEN
HCQ4Surfdefect: Hydroxychloroquine (HCQ) in pediatric ILD (interstitial lung disease) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Pädiatrische Pulmologie, Allergologie und Endokrinologie
OSTERREICH
WIEN
WIEN
COVID-19: Efficacy of solnatide to treat pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS - a pilot-trial (phase 2)
Allgemeines Krankenhaus der Stadt Wien
Universitätsklinik für klinische Pharmakologie
SPANIEN
Andalucía
SEVILLA
HCQ-chILD-EU: Hydroxychloroquine in pediatric ILD - START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group to evaluate the efficacy and safety of hydroxychloroquine (HCQ) (Phase II) - ES
Hospital Universitario Virgen del Rocío
Unidad de Pediatría
SPANIEN
Cataluña
BARCELONA
HCQ-chILD-EU: Hydroxychloroquine in pediatric ILD - START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group to evaluate the efficacy and safety of hydroxychloroquine (HCQ) (Phase II) - ES
Hospital Universitari Vall d'Hebron
Unidad de Neumología Pediátrica y Fibrosis Quística
SPANIEN
Cataluña
BARCELONA
SEAL: Safety and Efficacy of Inhaled Pegylated Adrenomedullin (PEG-ADM) in Patients Suffering From Acute Respiratory Distress Syndrome (ARDS): a Double-blind, Randomized, Placebo-controlled, Multicenter Phase 2a/b Clinical Trial - ES
Hospital Universitari Vall d'Hebron
Servicio de Medicina intensiva
SPANIEN
Cataluña
BARCELONA
SEAL: Safety and Efficacy of Inhaled Pegylated Adrenomedullin (PEG-ADM) in Patients Suffering From Acute Respiratory Distress Syndrome (ARDS): a Double-blind, Randomized, Placebo-controlled, Multicenter Phase 2a/b Clinical Trial - ES
Hospital de la Santa Creu i Sant Pau
Servicio de Medicina Intensiva
SPANIEN
Cataluña
SABADELL
SEAL: Safety and Efficacy of Inhaled Pegylated Adrenomedullin (PEG-ADM) in Patients Suffering From Acute Respiratory Distress Syndrome (ARDS): a Double-blind, Randomized, Placebo-controlled, Multicenter Phase 2a/b Clinical Trial - ES
Corporación Sanitaria Parc Taulí. Hospital de Sabadell
Servicio de Medicina intensiva
SPANIEN
Comunidad Valenciana
VALENCIA
HCQ-chILD-EU: Hydroxychloroquine in pediatric ILD - START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group to evaluate the efficacy and safety of hydroxychloroquine (HCQ) (Phase II) - ES
Hospital Clínico Universitario de Valencia
Servicio de Pediatría
SPANIEN
Madrid
MADRID
HCQ-chILD-EU: Hydroxychloroquine in pediatric ILD - START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group to evaluate the efficacy and safety of hydroxychloroquine (HCQ) (Phase II) - ES
Hospital Universitario 12 de Octubre
Servicio de Pediatría
SPANIEN
Madrid
MADRID
HCQ-chILD-EU: Hydroxychloroquine in pediatric ILD - START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group to evaluate the efficacy and safety of hydroxychloroquine (HCQ) (Phase II) - ES
Hospital Universitario La Paz
Servicio de Pediatría
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
SPIRIT: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis - BE
Erasme Hospital - ULB
Service de Pneumologie
BELGIEN
VLAAMS BRABANT
LEUVEN
A Long-Term Study to Assess the Ongoing Safety and Efficacy of Recombinant Human Acid Sphingomyelinase in Patients With Acid Sphingomyelinase Deficiency - BE
UZ Leuven - Campus Gasthuisberg
Centrum metabole ziekten - UZ Leuven
BELGIEN
VLAAMS BRABANT
LEUVEN
SCENIC trial: Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study With Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients With Idiopathic Pulmonary Fibrosis (IPF) - BE
UZ Leuven - Campus Gasthuisberg
Pneumology department
DEUTSCHLAND
Baden-Württemberg
HEIDELBERG
SCENIC-Studie: Randomisierte, doppelblinde, Placebo-kontrollierte, dosisabhängige, Wirksamkeits- und Sicherheitsstudie mit inhaliertem RVT-1601 zur Behandlung von anhaltendem Husten bei Patienten mit idiopathischer Lungenfibrose (IPF)
Thoraxklinik-Heidelberg gGmbH
Thoraxklinik Heidelberg
DEUTSCHLAND
Baden-Württemberg
HEIDELBERG
Eine randomisierte, doppelblinde, placebokontrollierte Phase-2-Studie zur Bewertung der Sicherheit, Verträglichkeit, biologischen Aktivität und PK von ND-L02-s0201 bei Patienten mit idiopathischer Lungenfibrose (IPF)
Thoraxklinik-Heidelberg gGmbH
Thoraxklinik Heidelberg
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Langzeitsicherheitsstudie von Tofacinib bei Patienten mit jugendlicher idiopathischer Arthritis -DE-
Institution: Information not provided - DE
DEUTSCHLAND
Hamburg
HAMBURG
Eine multizentrische, offene Studie zur Untersuchung der Pharmakokinetik, Sicherheit und Pharmakodynamik von subkutan verabreichtem Belimumab, einem humanen monoklonalen Anti-BLyS-Antikörper, plus Standardtherapie bei pädiatrischen Teilnehmern mit systemischem Lupus erythematodes (SLE) (Phase II)
Schön Klinik Hamburg Eilbek
Hamburger Zentrum für Kinder- und Jugendrheumatologie
DEUTSCHLAND
Hessen
FRANKFURT AM MAIN
Gentherapie für X-CGD (X-CGD-Version2): Phase I/II somatische Gentherapiestudie zur Behandlung der X-chromosomalen septischen Granulomatose
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
Medizinische Klinik II - Hämatologie, Onkologie, Hämostaseologie, Rheumatologie, Infektiologie
DEUTSCHLAND
Hessen
FRANKFURT AM MAIN
Phase I/II G1XCGD.01 Sudie: Nicht randomisierte, multizentrische, offene Phase I/II-Gentherapiestudie mit g1xcgd (Lentiviral Vector Transduced cd34+ Cells) zur Behandlung der X-chromosomalen chronischen Granulomatose
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
Medizinische Klinik II - Hämatologie, Onkologie, Hämostaseologie, Rheumatologie, Infektiologie
DEUTSCHLAND
Hessen
GIEßEN
Eine offene Verlängerungsstudie zur langfristigen Sicherheit von oralem BIBF 1120 bei Patienten mit idiopathischer Lungenfibrose (Phase III)
Med. Klinik und Poliklinik II des UKGM am Standort Gießen
Schwerpunkt Pneumologie und Intensivmedizin - Fibrosierende Lungenerkrankungen
DEUTSCHLAND
Hessen
IMMENHAUSEN
Eine randomisierte, doppelblinde, placebokontrollierte Phase-2-Studie zur Bewertung der Sicherheit, Verträglichkeit, biologischen Aktivität und PK von ND-L02-s0201 bei Patienten mit idiopathischer Lungenfibrose (IPF)
Lungenfachklinik Immenhausen
Zentrum für Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin
DEUTSCHLAND
Nordrhein-Westfalen
ESSEN
Eine multizentrische, offene einarmige Studie zur Untersuchung der Sicherheit und Verträglichkeit von Pirfenidone (Esbriet) in Kombination mit Nintedanib (Ofev) bei Patienten mit Idiopathischer Lungenfibrose (Phase IV)
Universitätsmedizin Essen - Ruhrlandklinik
Abteilung für Interventionelle Pneumologie
DEUTSCHLAND
Nordrhein-Westfalen
ESSEN
SCENIC-Studie: Randomisierte, doppelblinde, Placebo-kontrollierte, dosisabhängige, Wirksamkeits- und Sicherheitsstudie mit inhaliertem RVT-1601 zur Behandlung von anhaltendem Husten bei Patienten mit idiopathischer Lungenfibrose (IPF)
Universitätsmedizin Essen - Ruhrlandklinik
Klinik für Pneumologie
DEUTSCHLAND
Nordrhein-Westfalen
ESSEN
Eine randomisierte, doppelblinde, placebokontrollierte Phase-2-Studie zur Bewertung der Sicherheit, Verträglichkeit, biologischen Aktivität und PK von ND-L02-s0201 bei Patienten mit idiopathischer Lungenfibrose (IPF)
Universitätsmedizin Essen - Ruhrlandklinik
Klinik für Pneumologie
DEUTSCHLAND
Nordrhein-Westfalen
SANKT AUGUSTIN
Eine multizentrische, offene Studie zur Untersuchung der Pharmakokinetik, Sicherheit und Pharmakodynamik von subkutan verabreichtem Belimumab, einem humanen monoklonalen Anti-BLyS-Antikörper, plus Standardtherapie bei pädiatrischen Teilnehmern mit systemischem Lupus erythematodes (SLE) (Phase II)
Asklepios Kinderklinik Sankt Augustin GmbH
Abteilung für Allgemeine Kinder- und Jugendmedizin
DEUTSCHLAND
Rheinland-Pfalz
MAINZ
ASCEND: Eine multizentrische , randomisierte, doppelblinde , Placebo-kontrollierte Phase 2/3-Wiederholungsdosis-Studie zur Untersuchung der Wirksamkeit, Sicherheit, Pharmakodynamik und Pharmakokinetik von Olipudase alfa bei Patienten mit Säure-Sphingomyelinase-Mangel
Universitätsmedizin Mainz
Villa Metabolica - Schwerpunktbereich angeborene Stoffwechselerkrankungen
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis - FR
Institution: Information not provided - FR
FRANKREICH
GRAND-EST
NANCY
CURDYS: Exogenous Surfactant in Very Preterm Neonates Presenting With Severe Respiratory Distress in Prevention of Bronchopulmonary Dysplasia (phase IV) - FR
CHU de Nancy - Maternité régionale
Maternite Regionale Universitaire - CHU Nancy
FRANKREICH
ILE-DE-FRANCE
PARIS
EXCHANGE-IPF: Therapeutic Plasma Exchange, Rituximab and Intravenous Immunoglobulins for Severe Acute Exacerbation of Idiopathic Pulmonary Fibrosis Admitted in ICU: an Open, Randomized, Controlled Trial.
CHU Paris Nord-Val de Seine - Hôpital Xavier Bichat-Claude Bernard
Service de pneumologie A
FRANKREICH
ILE-DE-FRANCE
PARIS
EXAFIP : Cyclophosphamide Added to Corticosteroid in the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Placebo-controlled Randomized Trial (Phase III)
Groupe hospitalier AP-HP.6 - Hôpital Tenon
Unité Pneumologie - Oncologie Thoracique - Maladies Pulmonaires Rares
FRANKREICH
ILE-DE-FRANCE
PARIS
A Phase I/II, Non Randomized, Monocentric Open-label Study of Autologous CD34+ Cells Transduced With the G1XCGD Lentiviral Vector in Patients With X-Linked Chronic Granulomatous Disease
Hôpital Necker-Enfants Malades
Service d'Immuno-hématologie pédiatrique
FRANKREICH
ILE-DE-FRANCE
PARIS
A French open-label extension study of canakinumab in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) who participated in the international phase III study CACZ885G2301E1
Hôpital Necker-Enfants Malades
Service d'Immuno-hématologie pédiatrique - Rhumatologie
ITALIEN
TOSCANA
FIRENZE
A Randomized, Open, Multinational, Multicentre,2-Part Study In Spontaneously Breathing Preterm Neonates With Mild To Moderate Respiratory Distress Syndrome (RDS) To Investigate The Safety, Tolerability And Efficacy Of Inhaled Nebulised Poractant Alfa (Porcine Surfactant, Curosurf®) In Comparison With Nasal Continuous Positive Airway Pressure (nCPAP) Alone - IT
Azienda Ospedaliero Universitaria Careggi
S.O.D. Neonatologia e Terapia Intensiva Neonatale
NIEDERLANDE
Noord-Holland
AMSTERDAM
ASCEND: A Phase 2/3, Multicenter, Randomized, Double-blinded, Placebo-controlled, Repeat-dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency - NL
Amsterdam UMC, locatie AMC
Afdeling Erfelijke Stofwisselingsziekten
NIEDERLANDE
Utrecht
UTRECHT
Gastrointestinal side effects of MTX in patients with JIA: Phase III effectiveness multicenter randomized clinical trial in Patients with Juvenile Idiopathic Arthritis and Methotrexate (MTX) related side effects: Psychological Behavioural therapy versus switch to MTX parenteral versus standard of care
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
NIEDERLANDE
Zuid-Holland
LEIDEN
BeSt for kids: A randomized clinical intervention trial to test the effectiveness of different treatment strategies in patients with Juvenile Idiopathic Arthritis
LUMC - Leids Universitair Medisch Centrum
Willem-Alexander Kinderziekenhuis
OSTERREICH
STEIERMARK
GRAZ
A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally (Phase 2) - AT
Medizinische Universität Graz
Klinische Abteilung für Pulmonologie
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
A Randomized, Open, Multinational, Multicentre,2-Part Study In Spontaneously Breathing Preterm Neonates With Mild To Moderate Respiratory Distress Syndrome (RDS) To Investigate The Safety, Tolerability And Efficacy Of Inhaled Nebulised Poractant Alfa (Porcine Surfactant, Curosurf®) In Comparison With Nasal Continuous Positive Airway Pressure (nCPAP) Alone (Phase 2) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
JUVE-BASIS: A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA) (Phase 3) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
JUVE-X: A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
ARTEMIS-IGAN: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
WIEN
GOOD-IDES: An Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Nephrologie und Dialyse
PORTUGAL
SUL
LISBOA
A Phase II Open Label, Roll Over Study of the Long Term Tolerability, Safety and Efficacy of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis - PT
Hospital de Sta. Maria - Centro Hospitalar de Lisboa Norte, EPE.
Serviço de Pneumologia
SCHWEIZ
Suisse Alémanique
ZÜRICH
Surfactant Nebulization for the Early Aeration of the Preterm Lung: a Single Blinded, Parallel, Randomized Controlled Trial
Universitätspital Zürich
Klinik für Neonatologie
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A pilot, open-label, single arm, multicenter study to evaluate safety, tolerability, pharmacokinetics and efficacy of intravenous administrations of NI-0501, an anti-interferon gamma (anti-IFN?) monoclonal antibody, in patients with systemic Juvenile Idiopathic Arthritis (sJIA) developing Macrophage Activation Syndrome/secondary HLH(MAS/sHLH)-GB
Institution: Information not provided - CH
SPANIEN
Andalucía
SEVILLA
JUVE-X: A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA) - ES
Hospital Universitario Virgen del Rocío
Unidad de Pediatría
SPANIEN
Aragón
ZARAGOZA
ELIKIDS: Open label, Two Cohort (with and without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients with Gaucher Disease Type 1 and Type 3 (Phase III) - ES
Hospital Quirónsalud Zaragoza
Servicio de Hematología
SPANIEN
Cantabria
SANTANDER
ISABELA1: A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis - ES
Hospital Universitario Marqués de Valdecilla
Servicio de Neumología
SPANIEN
Cataluña
BARCELONA
SPANIEN
Cataluña
BARCELONA
ISABELA1: A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis - ES
Hospital Clínic de Barcelona
Servicio de Neumología y Alergia Respiratoria
SPANIEN
Cataluña
ESPLUGUES DE LLOBREGAT
ELIKIDS: Open label, Two Cohort (with and without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients with Gaucher Disease Type 1 and Type 3 (Phase III) - ES
Hospital Sant Joan de Déu Barcelona
Unidad de Enfermedades Metabólicas Congénitas
SPANIEN
Cataluña
ESPLUGUES DE LLOBREGAT
A multi-center, open-label trial to evaluate the pharmacokinetics, safety, and pharmacodynamics of subcutaneously administered belimumab, a human monoclonal anti-BLyS antibody, plus standard therapy in pediatric participants with systemic lupus erythematosus (SLE) (Phase II) - ES
Hospital Sant Joan de Déu Barcelona
Unidad de Reumatología
SPANIEN
Cataluña
ESPLUGUES DE LLOBREGAT
JUVE-X: A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA) - ES
Hospital Sant Joan de Déu Barcelona
Unidad de Reumatología
SPANIEN
Cataluña
L'HOSPITALET DE LLOBREGAT
ISABELA1: A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis - ES
Hospital Universitari de Bellvitge
Servicio de Neumología
SPANIEN
Comunidad Valenciana
VALENCIA
ISABELA1: A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis - ES
Hospital General Universitario de Valencia
Servicio de Neumología
SPANIEN
Comunidad Valenciana
VALENCIA
A multi-center, open-label trial to evaluate the pharmacokinetics, safety, and pharmacodynamics of subcutaneously administered belimumab, a human monoclonal anti-BLyS antibody, plus standard therapy in pediatric participants with systemic lupus erythematosus (SLE) (Phase II) - ES
Hospital Universitario y Politécnico La Fe
Unidad de Reumatología Pediátrica
SPANIEN
Comunidad Valenciana
VALENCIA
JUVE-X: A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA) - ES
Hospital Universitario y Politécnico La Fe
Unidad de Reumatología Pediátrica
SPANIEN
Galicia
A CORUÑA
JUVE-X: A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA) - ES
Hospital Universitario da Coruña
Servicio de Reumatología
SPANIEN
Galicia
VIGO
ISABELA1: A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis - ES
Hospital Álvaro Cunqueiro
Servicio de Neumología
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
Long-Term Safety Study Of Tofacinib In Patients With Juvenile Idiopathic Arthritis - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
PROTECT: A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
NefIgArd: A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients with IgA Nephropathy - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally (Phase 2) - ES
Institution: Information not provided - ES
SPANIEN
Madrid
MADRID
An adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients (Phase II) - ES
Hospital Clínico San Carlos
SPANIEN
Madrid
MADRID
ISABELA1: A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis - ES
Hospital Clínico San Carlos
Servicio de Neumología
SPANIEN
Madrid
MADRID
JUVE-X: A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA) - ES
Hospital Infantil Universitario Niño Jesús
Unidad de Reumatología
SPANIEN
Madrid
MADRID
An adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients (Phase II) - ES
Hospital Universitario 12 de Octubre
SPANIEN
Madrid
MADRID
JUVE-X: A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA) - ES
Hospital Universitario La Paz
Servicio de Reumatología
SPANIEN
Madrid
MADRID
ASCEND: A phase 2/3, multicenter, randomized, double-blinded, placebo-controlled, repeatdose, dose-comparison study to evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of olipudase alfa in patients with acid sphingomyelinase deficiency - ES
Hospital Universitario Ramón y Cajal
Servicio de Hematología y Hemoterapia
SPANIEN
Madrid
MADRID
A multi-center, open-label trial to evaluate the pharmacokinetics, safety, and pharmacodynamics of subcutaneously administered belimumab, a human monoclonal anti-BLyS antibody, plus standard therapy in pediatric participants with systemic lupus erythematosus (SLE) (Phase II) - ES
Hospital Universitario Ramón y Cajal
Servicio de Reumatología
SPANIEN
Madrid
MADRID
JUVE-X: A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA) - ES
Hospital Universitario Ramón y Cajal
Servicio de Reumatología
SPANIEN
Madrid
MADRID
ISABELA1: A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis - ES
Hospital Universitario de la Princesa
Servicio de Neumología
SPANIEN
Navarra
PAMPLONA
ISABELA1: A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis - ES
Clínica Universidad de Navarra
Departamento de Neumología
SPANIEN
País Vasco
BARAKALDO
ELIKIDS: Open label, Two Cohort (with and without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients with Gaucher Disease Type 1 and Type 3 (Phase III) - ES
Hospital Universitario Cruces
Servicio de Pediatría
VEREINIGTE STAATEN
Georgia
ATLANTA
VEREINIGTE STAATEN
Michigan
DETROIT
Aerosolized Survanta in Neonatal Respiratory Distress Syndrome: Phase I/II Study - US
Wayne State University
VEREINIGTE STAATEN
Texas
DALLAS
LEAP: A 52-week Two-part, Open-label, Multicenter, Multinational Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 (Phase II) - US
Baylor University Medical Center
Institute of Metabolic Disease
VEREINIGTES KONIGREICH
Avon
BRISTOL
VEREINIGTES KONIGREICH
Cambridgeshire
CAMBRIDGE
SPIRIT: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis-GB
Addenbrooke's Hospital
Addenbrookes Hospital
VEREINIGTES KONIGREICH
Greater London
LONDON
A Long-Term Study to Assess the Ongoing Safety and Efficacy of Recombinant Human Acid Sphingomyelinase in Patients With Acid Sphingomyelinase Deficiency - UK
GOSH NHS Foundatin Trust
Great Ormond Street Hospital
VEREINIGTES KONIGREICH
Greater London
LONDON
A phase I/II, non randomized, multicenter, open-label study of G1XCGD (lentiviral vector transduced CD34+ cells) in patients with X-Linked Chronic Granulomatous Disease - UK
Great Ormond Street Hospital
Molecular and Cellular Immunology Unit
VEREINIGTES KONIGREICH
Greater Manchester
ADDRESS: NOT PROVIDED - UK
ATLAS Study: A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis -GB
Institution: Information not provided - UK
VEREINIGTES KONIGREICH
Norfolk
NORWICH
The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC)
University of East Anglia HQ
University of East Anglia
VEREINIGTES KONIGREICH
North Yorkshire
COTTINGHAM
VEREINIGTES KONIGREICH
Nottinghamshire
NOTTINGHAM
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)GB
LAM Action Nottingham, Voluntary Action Centre
Division of Respiratory Medicine, Clinical Sciences Building
BULGARIEN
South-West region
SOFIA
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - BG -
University Hospital Alexandrovska
Clinic of Hematology
DEUTSCHLAND
Bayern
GARMISCH-PARTENKIRCHEN
ß-SPECIFIC 4 Patients: Eine offene Studie zur Beurteilung der Wirksamkeit und Sicherheit von Canakinumab (wenn die Dosis reduziert wird oder das Dosisintervall verlängert wird) bei Patienten mit systemischer juveniler idiopathischer Arthritis (Phase III) - DE
Kinderklinik Garmisch-Partenkirchen gGmbH
Deutsches Zentrum für Kinder- und Jugendrheumatologie
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Langfristige Verlängerungsstudie zur Beurteilung der Sicherheit und Wirksamkeit von subkutanem Tocilizumab bei Patienten mit polyartikulär verlaufender und systemischer juveniler idiopathischer Arthritis.
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Eine offene, sequentielle, aufsteigende, wiederholte Dosisfindungsstudie von Sarilumab, verabreicht mit subkutaner (SC) Injektion, bei Kindern und Jugendlichen im Alter von 2 bis 17 Jahren, mit Polyartikulärer Juveniler Idiopathischer Arthritis (pcJIA), gefolgt von einer Verlängerungsphase (Phase II).
Institution: Information not provided - DE
FRANKREICH
ILE-DE-FRANCE
CLICHY
ENCORE : A phase 3, randomized, multi-center, multi-national, open-label, active comparator study to evaluate the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 who have reached therapeutic goals with enzyme replacement therapy - FR -
CHU Paris Nord-Val de Seine - Hôpital Beaujon
Service de médecine interne
FRANKREICH
ILE-DE-FRANCE
LE KREMLIN-BICÊTRE
Long-Term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Polyarticular-Course and Systemic Juvenile Idiopathic Arthritis (Phase I) - FR
CHU Paris-Sud - Hôpital de Bicêtre
Service de Rhumatologie pédiatrique
FRANKREICH
ILE-DE-FRANCE
PARIS
PEXIVAS: Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis. An International Randomised Controlled Trial (phase III) - FR
CHU Paris Centre - Hôpital Cochin, Site Cochin
Unité fonctionnelle de Médecine interne et centre de référence maladies rares
FRANKREICH
ILE-DE-FRANCE
PARIS
AJIBIOREM : Treatment Tapering in Oligoarticular or Rheumatoid Factor Negative Polyarticular Juvenile Idiopathic Arthritis With Inactive Disease on Biologic Therapy (Phase III)
Hôpital Necker-Enfants Malades
Service d'Immuno-hématologie pédiatrique - Rhumatologie
FRANKREICH
ILE-DE-FRANCE
PARIS
Evaluation of the Efficacy of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis: Randomized Double-blind Placebo-controlled Trial - FR
Hôpital Necker-Enfants Malades
Service de Génétique Moléculaire
ISRAEL
ISRAEL
PETAH TIKVA
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - IL -
Rabin Medical Center - Beilinson Hospital
Recanati Genetic Institute
ITALIEN
CAMPANIA
NAPOLI
Efficacy and safety of treatment with miglustat in patients with Niemann-Pick disease type c
Azienda Ospedaliera Universitaria "Federico II"
Laboratorio Dipartimento di Pediatria
ITALIEN
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Long-Term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Polyarticular-Course and Systemic Juvenile Idiopathic Arthritis - IT
Institution: Information not provided - IT
ITALIEN
FRIULI VENEZIA GIULIA
UDINE
ENCORE : A phase 3, randomized, multi-center, multi-national, open-label, active comparator study to evaluate the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 who have reached therapeutic goals with enzyme replacement therapy - IT -
Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" di Udine
Centro di Coordinamento Regionale per le Malattie Rare
ITALIEN
PUGLIA
BARI
Combined Therapy With Peg-Interferon alpha, Ribavirin And Rituximab Of Hepatitis C Virus-Related Mixed Cryoglobulinemia - IT
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Unità di Epatologia - Sezione di Medicina Interna e Oncologia Clinica
LIBANON
Beyrouth
BEIRUT
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - LB -
Hôtel-Dieu de France, Université Saint-Joseph
Oncology & Hematology
NIEDERLANDE
Utrecht
UTRECHT
B-Vit in JIA: Modulating regulatory T cell function in JIA with Vitamin B3 (nicotinamide) treatment
UMC Utrecht - Universitair Medisch Centrum Utrecht
Kinderreumacentrum
NIEDERLANDE
Utrecht
UTRECHT
VAART trial: Multicenter randomized clinical intervention trial in Patients with Juvenile Idiopathic Athritis (JIA) - Safety and efficacy of vaccination with live attenuated Measles-Mumps-Rubella vaccine
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
NIEDERLANDE
Utrecht
UTRECHT
A Randomized, Placebo-controlled Study to Evaluate the Effect of Tocilizumab on Disease Response in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA), With an Open-label Extension to Examine the Long Term Use of Tocilizumab (Phase III) - NL
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
NIEDERLANDE
Utrecht
UTRECHT
CLIPPER2: An Open-label Extension Study to Assess the Long-term Safety and Clinical Benefit of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-related Arthritis, Or Psoriatic Arthritis Who Were Previously Enrolled in Protocol 0881A1-3338-ww (Phase II-III) - NL
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
NIEDERLANDE
Utrecht
UTRECHT
Beta-SPECIFIC 3: An Open-label Extension Study of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations Who Participated in Studies ACZ885G2301 and ACZ885G2305; and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever (Phase III) - NL
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
NIEDERLANDE
Utrecht
UTRECHT
Beta-SPECIFIC 4Pa: An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) (Phase III) - NL
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
NIEDERLANDE
Utrecht
UTRECHT
ESTIS trial: Biomarker-guided treatment-and-stop-strategy for recombinant IL-1receptor antagonist (anakinra) in patients with systemic Juvenile Idiopathic Arthritis
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
NIEDERLANDE
Zuid-Holland
LEIDEN
CHAMP: Children with Arthritis: Monotherapy or Polytherapy. A multicentre, single-blinded, randomized treat to target, one-year follow-up clinical trial in patients with recent onset Juvenile Idiopathic Arthritis (Phase IV).
LUMC - Leids Universitair Medisch Centrum
Willem-Alexander Kinderziekenhuis
OSTERREICH
STEIERMARK
GRAZ
ANCA_CGM: Influence of once vs twice daily corticosteroid administration on glycemia assessed by continuous glucose monitoring in patients with ANCA vasculitis (phase 4)
Medizinische Universität Graz
Klinische Abteilung für Nephrologie
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
JUVE-BALM: A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 1 Year to Less than 18 Years Old with Systemic Juvenile Idiopathic Arthritis (sJIA) (Phase 3) - AT
Institution: Information not provided - AT
SPANIEN
Cataluña
BARCELONA
Arimoclomol prospective double blind, randomised, placebo-controlled study in patients diagnosed with Niemann-Pick disease type C (Phase II-III)- ES
Hospital Universitari Vall d'Hebron
Servicio de Neurología Pediátrica
SPANIEN
Cataluña
ESPLUGUES DE LLOBREGAT
CLIPPER2: An Open-label Extension Study to Assess the Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-related Arthritis, Or Psoriatic Arthritis Who Were Previously Enrolled in Protocol 0881A1-3338-ww (Phase II-III) - ES
Hospital Sant Joan de Déu Barcelona
Unidad de Reumatología
SPANIEN
Cataluña
L'HOSPITALET DE LLOBREGAT
Effects of N-Acetyl-L-Leucine on Niemann-Pick type C Disease (NPC): A multinational, multi-center, open-label, rater-blinded Phase II study - ES
Hospital Universitari de Bellvitge
Servicio de Neurología
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, with Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Followed by an Extension Phase - ES
Institution: Information not provided - ES
TSCHECHISCHE REPUBLIK
Capital City Prague
PRAHA
ENCORE : A phase 3, randomized, multi-center, multi-national, open-label, active comparator study to evaluate the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 who have reached therapeutic goals with enzyme replacement therapy - CZ -
Charles University - First faculty of medicine
National Centre for Treatment of Gaucher Disease
TUNESIEN
TUNISIA
TUNIS
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - TN -
Hôpital La Rabta
Service de Pédiatrie
TURKEI
TURKEY
IZMIR
ENCORE : A phase 3, randomized, multi-center, multi-national, open-label, active comparator study to evaluate the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 who have reached therapeutic goals with enzyme replacement therapy - TR -
Ege Üniversitesi
Department of Pediatrics - Cocuk asgligi ve Hastaliklari Anabilim Dali
VEREINIGTES KONIGREICH
Greater London
LONDON
ENDURRANCE-1: Exploring durable remission with rituximab in ANCA associated vasculitis-GB
Imperial College London, main campus
Imperial College London Headquarters
VEREINIGTES KONIGREICH
Greater London
LONDON
ENDURRANCE-1: Exploring durable remission with rituximab in ANCA associated vasculitis-GB
Imperial College NHS Trust
VEREINIGTES KONIGREICH
Merseyside
LIVERPOOL
DEUTSCHLAND
Baden-Württemberg
MANNHEIM
Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Universitätsmedizin Mannheim
Universitätsklinikum Mannheim
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Mepolizumab Langzeitzugangsprogramm für Probanden, die an der Studie MEA115921 (Placebo-kontrollierte Studie von Mepolizumab zur Behandlung von eosinophiler Granulomatose mit Polyangiitis bei Probanden mit Standardtherapie) teilgenommen haben. - DE-
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
BERLIN
Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Charité - Universitätsmedizin Berlin
DEUTSCHLAND
Nordrhein-Westfalen
ESSEN
Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Universitätsklinikum Essen
DEUTSCHLAND
Nordrhein-Westfalen
MÜNSTER
Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Universitätsklinikum Münster
DEUTSCHLAND
Sachsen
DRESDEN
Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Universitätsklinikum Dresden
DEUTSCHLAND
Thüringen
JENA
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-care Therapy) - FR
Institution: Information not provided - FR
FRANKREICH
AUVERGNE-RHONE-ALPES
PIERRE-BENITE
MAINEPSAN Study: A Prospective Comparative Randomized Double-blind Placebo-controlled In-Parallel Groups Multicenter, Study to Evaluate the remission MAINtenance using Extended administration of Prednisone in Systemic anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis
CHU de Lyon HCL - GH Sud
Service de médecine interne et pathologie vasculaire
FRANKREICH
ILE-DE-FRANCE
PARIS
CHUSPAN2 : Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Churg Strauss Syndrome Without Poor Prognosis Factors (Phase III)
CHU Paris Centre - Hôpital Cochin, Site Cochin
Unité fonctionnelle de Médecine interne et centre de référence maladies rares
NIEDERLANDE
Groningen
GRONINGEN
Prevention of Relapses in Proteinase 3 (PR3)-Anti-Neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
UMCG - Universitair Medisch Centrum Groningen
Afdeling Nefrologie
NIEDERLANDE
Utrecht
UTRECHT
GO KIDS: A Multicenter, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab, a Humanized Anti-TNFa Antibody, in Subjects With Active Polyarticular Juvenile Idiopathic Arthritis (JIA) Despite Standard Therapy (Phase III) - NL
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
SPANIEN
Andalucía
SEVILLA
IXchange: A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - ES
Hospital Quirónsalud Infanta Luisa
SPANIEN
Andalucía
SEVILLA
IXchange: A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - ES
Hospital Universitario Virgen de Valme
SPANIEN
Andalucía
SEVILLA
IXchange: A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - ES
Hospital Universitario Virgen del Rocío
SPANIEN
Cataluña
BADALONA
IXchange: A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - ES
Hospital Germans Trias I Pujol
SPANIEN
Cataluña
BARCELONA
SPANIEN
Cataluña
BARCELONA
IXchange: A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - ES
Hospital Clínic de Barcelona
SPANIEN
Cataluña
BARCELONA
IXchange: A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - ES
Hospital Universitari Vall d'Hebron
SPANIEN
Cataluña
L'HOSPITALET DE LLOBREGAT
IXchange: A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - ES
Hospital Universitari de Bellvitge
SPANIEN
Madrid
ALCORCÓN
IXchange: A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - ES
Hospital Universitario Fundación Alcorcón
SPANIEN
Madrid
FUENLABRADA
IXchange: A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - ES
Hospital Universitario de Fuenlabrada
VEREINIGTES KONIGREICH
Cambridgeshire
CAMBRIDGE
CCRN 2438: A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard of Care Therapy (Phase III) - UK
Addenbrooke's Hospital
Addenbrookes Hospital
Multinationale klinische Studie(n)
SCHWEIZ
Suisse Alémanique
BASEL
Multicenter, International, Double-blind, Two-Arm, Randomized, Placebo-controlled Phase II Trial of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing ILD
Hoffmann-La Roche
Hoffmann - La Roche Ltd.
VEREINIGTES KONIGREICH
Greater London
LONDON
BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care.
King's College London
King's College London Headquarters
DANEMARK
Jylland
ADDRESS: NOT PROVIDED - DK
A Randomised, Double-Blind, Placebo-Controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary AlveoLAr Proteinosis Patients IMPALA
Institution: Information not provided - DK
FINNLAND
Finland
TURKU
TRAUMAKINE: Interferon-beta treatment of acute respiratory distress syndrome (ARDS)
Faron Pharmaceuticals Limited
SCHWEIZ
Suisse Alémanique
BASEL
EXIST-2: Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
Novartis International AG
VEREINIGTES KONIGREICH
Greater London
LONDON
DeVENT: Decision Support System to Evaluate VENTilation in ARDS (acute respiratory distress syndrome)
Imperial College London, main campus
Imperial College London Headquarters
BELGIEN
VLAAMS BRABANT
MECHELEN
DEUTSCHLAND
Rheinland-Pfalz
INGELHEIM AM RHEIN
A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF) (Phase III) coordination
Boehringer Ingelheim Pharma GmbH & Co. KG
Boehringer Ingelheim Pharma GmbH
FRANKREICH
ILE-DE-FRANCE
EVRY
NET4CGD: Gene Therapy for X-linked Chronic Granulomatous Disease (CGD)
Généthon
Centre de Recherche Généthon
ITALIEN
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Randomized, Open, Multinational, Multicentre,2-Part Study In Spontaneously Breathing Preterm Neonates With Mild To Moderate Respiratory Distress Syndrome (RDS) To Investigate The Safety, Tolerability And Efficacy Of Inhaled Nebulised Poractant Alfa (Porcine Surfactant, Curosurf®) In Comparison With Nasal Continuous Positive Airway Pressure (nCPAP) Alone
Institution: Information not provided - IT
SCHWEIZ
Suisse Alémanique
ALLSCHWIL
MUSIC: A Double-blind, Randomized, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Macitentan in Patients With Idiopathic Pulmonary Fibrosis (Phase II) (coordination)
Actelion Pharmaceuticals Ltd.
SCHWEIZ
Suisse Alémanique
ALLSCHWIL
BUILD 3 - Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter double-blind randomized placebo-controlled, parallel group, event-driven, group sequential, phase III study (coordination)
Actelion Pharmaceuticals Ltd.
SCHWEIZ
Suisse Alémanique
BASEL
A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Sildenafil Added to Pirfenidone in Patients With Advanced Idiopathic Pulmonary Fibrosis and Risk of Group 3 Pulmonary Hypertension
Hoffmann-La Roche
Hoffmann - La Roche Ltd.
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A pilot, open-label, single arm, multicenter study to evaluate safety, tolerability, pharmacokinetics and efficacy of intravenous administrations of NI-0501, an anti-interferon gamma (anti-IFN?) monoclonal antibody, in patients with systemic Juvenile Idiopathic Arthritis (sJIA) developing Macrophage Activation Syndrome/secondary HLH(MAS/sHLH)
Institution: Information not provided - CH
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
PANORAMA: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N-Acetylcysteine in Patients With Idiopathic Pulmonary Fibrosis With Background Treatment of Pirfenidone
Institution: Information not provided - CH
VEREINIGTE STAATEN
Massachusetts
CAMBRIDGE
VEREINIGTE STAATEN
Massachusetts
CAMBRIDGE
VEREINIGTE STAATEN
New York
NEW YORK
VEREINIGTE STAATEN
New York
NEW YORK
Long-Term Safety Study Of Tofacinib In Patients With Juvenile Idiopathic Arthritis (Phase II-III)
Pfizer, Inc.
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis
Institution: Information not provided - US
VEREINIGTES KONIGREICH
Essex
HARLOW
A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Participants with Systemic Lupus Erythematosus (SLE)
GlaxoSmithKline Research & Development Ltd.
GlaxoSmithKline Research & Development Limited
KANADA
Alberta
MOUNTAIN VIEW
NIEDERLANDE
Noord-Holland
NAARDEN
NIEDERLANDE
Utrecht
ADDRESS: NOT PROVIDED - NL
EDGE: A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once Daily versus Twice Daily Dosing of Genz-112638 in Patients with Gaucher Disease Type 1 who have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Institution: Information not provided - NL
NIEDERLANDE
Utrecht
WOERDEN
Oral Miglustat in Adult patients With Stable Type 1 Gaucher Disease (Phase III) (coordination)
Actelion Pharmaceuticals Nederland B.V.
SCHWEIZ
Suisse Alémanique
BASEL
Long-Term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Polyarticular-Course and Systemic Juvenile Idiopathic Arthritis
Hoffmann-La Roche
Hoffmann - La Roche Ltd.
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
Beta-SPECIFIC 4Pa: An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) (Phase III)
Institution: Information not provided - CH
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
An Open-label Extension Study of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations Who Participated in Studies ACZ885G2301 and ACZ885G2305; and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever
Institution: Information not provided - CH
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Randomized, Placebo-controlled Study to Evaluate the Effect of Tocilizumab on Disease Response in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA), With an Open-label Extension to Examine the Long Term Use of Tocilizumab (Phase III) - coordination
Institution: Information not provided - CH
VEREINIGTE STAATEN
Pennsylvania
PHILADELPHIA
PEXIVAS: Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial (phase III) (coordination)
Hospital of the University of Pennsylvania
Rheumatology Division
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, with Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Followed by an Extension Phase
Institution: Information not provided - US
VEREINIGTES KONIGREICH
Greater Manchester
ADDRESS: NOT PROVIDED - UK
CLIPPER2: An Open-label Extension Study to Assess the Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-related Arthritis, Or Psoriatic Arthritis Who Were Previously Enrolled in Protocol 0881A1-3338-ww (Phase II-III) (Coordination)
Institution: Information not provided - UK
DEUTSCHLAND
Thüringen
JENA
VEREINIGTES KONIGREICH
Oxfordshire
BEGBROKE